Concentration of health care expenditures in the U.S. civilian noninstitutionalized population

Guidance for clinical investigators, institutional review boards, and sponsors process for handling referrals to FDA under 21 CFR 50.54 : additional safeguards for children in clinical investigations

The role of social and behavioral sciences in public health : hearing before the Subcommittee on Research and Science Education, Committee on Science and Technology, House of Representatives, One Hundred Tenth Congress, second session, September 18, 2008

Research on the comparative effectiveness of medical treatments, options for an expanded federal role Statement of Peter R. Orszag, Director, before the Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives

Research on the comparative effectiveness of medical treatments issues and options for an expanded federal role

Evidence on the costs and benefits of health information technology

Information sheet guidance for institutional review boards and clinical investigators ("off-label" and investigational use of marketed drugs, biologics, and medical devices)

Information sheet guidance for institutional review boards and clinical investigators (use of investigational products when subjects enter a second institution)

Information sheet guidance for institutional review boards and clinical investigators (charging for investigational products)

Information sheet guidance for institutional review boards and clinical investigators (continuing review after study approval)